ArticleScientific reports2025
High doses of methylprednisolone causes substantial muscle loss with minimal impact on bone mass and architecture in C57BL/6JRj and RjOrl:SWISS mice.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucocorticoids are widely used to treat chronic autoimmune and inflammatory disorders. Unfortunately, glucocorticoid treatment frequently results in severe adverse effects, such as skeletal muscle atrophy and glucocorticoid-induced osteoporosis (GIO). Developing a reliable small animal model of GIO has been challenging, especially in achieving consistent bone loss, microstructural deterioration, and reduced bone strength. The study aimed to develop a robust small animal model to evaluate the effects of high doses of methylprednisolone (MP) on muscle and bone tissue simultaneously. Two strains of female mice, C57BL/6JRj (C57) and RjOrl: SWISS (SWISS), were divided into four groups each: (1) Control, (2) MP 15 mg/kg/day, (3) MP 22.5 mg/kg/day, and (4) MP 30 mg/kg/day. While MP caused a reduction in muscle volume in both strains, it did not result in consistent bone deterioration in either strain. Furthermore, the sparse bone loss manifested differently in the two strains. Therefore, although high-dose MP effectively induced muscle atrophy, further refinement is needed in order to achieve consistent bone deterioration. Moreover, unlike previous studies, the musculoskeletal system of SWISS mice did not exhibit greater susceptibility to MP compared to that of C57 mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.